KDR and neoplasm: Immunohistochemical analysis of Ki67, VEGFR-2, VEGF and CD31 also revealed that EriB treatment inhibited tumor cells proliferation, tumor angiogenesis, which may partly explain the anti-tumor activity of EriB in vivo.